Loading company…
Turnstone Biologics Corp. develops tumor infiltrating lymphocyte cancer immunotherapies, including the TIDAL-01 candidate.
Founded in 2018 in La Jolla, US, Turnstone Biologics Corp. develops cancer immunotherapies, mainly tumor infiltrating lymphocyte (TIL) therapies, including its Selected TILs platform and flagship TIDAL-01. David Stojdl is the founder. The company raised USD 80.00 mn in its July 20, 2023 IPO, selling 6.6 million shares at USD 12 per share on NASDAQ under the ticker TSBX, and has completed five deals; the listed stage is Series D.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in